1
|
IFP35 Is a Relevant Factor in Innate Immunity, Multiple Sclerosis, and Other Chronic Inflammatory Diseases: A Review. BIOLOGY 2021; 10:biology10121325. [PMID: 34943240 PMCID: PMC8698480 DOI: 10.3390/biology10121325] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/12/2021] [Accepted: 12/13/2021] [Indexed: 02/03/2023]
Abstract
Simple Summary In this review, we focused on the emerging role of IFP35, a highly conserved leucine zipper protein from fish to humans, with a still unknown biological function. The considered literature indicates this protein as a key-pleiotropic factor reflecting JAK-STAT and DAMPs pathways activation in innate immunity-dependent inflammation, as well as in the physiology and general pathology of a wide range of phylogenetically distant organisms. These findings also indicate IFP35 as a biologically relevant molecule in human demyelinating diseases of the central nervous system, including Multiple Sclerosis, and other organ-specific chronic inflammatory disorders. Abstract Discovered in 1993 by Bange et al., the 35-kDa interferon-induced protein (IFP35) is a highly conserved cytosolic interferon-induced leucine zipper protein with a 17q12-21 coding gene and unknown function. Belonging to interferon stimulated genes (ISG), the IFP35 reflects the type I interferon (IFN) activity induced through the JAK-STAT phosphorylation, and it can homodimerize with N-myc-interactor (NMI) and basic leucine zipper transcription factor (BATF), resulting in nuclear translocation and a functional expression. Casein kinase 2-interacting protein-1 (CKIP-1), retinoic acid-inducible gene I (RIG-I), and laboratory of genetics and physiology 2 Epinephelus coioides (EcLGP2) are thought to regulate IFP35, via the innate immunity pathway. Several in vitro and in vivo studies on fish and mammals have confirmed the IFP35 as an ISG factor with antiviral and antiproliferative functions. However, in a mice model of sepsis, IFP35 was found working as a damage associated molecular pattern (DAMP) molecule, which enhances inflammation by acting in the innate immune-mediated way. In human pathology, the IFP35 expression level predicts disease outcome and response to therapy in Multiple Sclerosis (MS), reflecting IFN activity. Specifically, IFP35 was upregulated in Lupus Nephritis (LN), Rheumatoid Arthritis (RA), and untreated MS. However, it normalized in the MS patients undergoing therapy. The considered data indicate IFP35 as a pleiotropic factor, suggesting it as biologically relevant in the innate immunity, general pathology, and human demyelinating diseases of the central nervous system.
Collapse
|
2
|
Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods. 3 Biotech 2020; 10:422. [PMID: 33251083 PMCID: PMC7679428 DOI: 10.1007/s13205-020-02406-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 08/20/2020] [Indexed: 12/15/2022] Open
Abstract
The goal of the present investigation is to identify the differentially expressed genes (DEGs) between SARS-CoV-2 infected and normal control samples to investigate the molecular mechanisms of infection with SARS-CoV-2. The microarray data of the dataset E-MTAB-8871 were retrieved from the ArrayExpress database. Pathway and Gene Ontology (GO) enrichment study, protein–protein interaction (PPI) network, modules, target gene–miRNA regulatory network, and target gene–TF regulatory network have been performed. Subsequently, the key genes were validated using an analysis of the receiver operating characteristic (ROC) curve. In SARS-CoV-2 infection, a total of 324 DEGs (76 up- and 248 down-regulated genes) were identified and enriched in a number of associated SARS-CoV-2 infection pathways and GO terms. Hub and target genes such as TP53, HRAS, MAPK11, RELA, IKZF3, IFNAR2, SKI, TNFRSF13C, JAK1, TRAF6, KLRF2, CD1A were identified from PPI network, target gene–miRNA regulatory network, and target gene–TF regulatory network. Study of the ROC showed that ten genes (CCL5, IFNAR2, JAK2, MX1, STAT1, BID, CD55, CD80, HAL-B, and HLA-DMA) were substantially involved in SARS-CoV-2 patients. The present investigation identified key genes and pathways that deepen our understanding of the molecular mechanisms of SARS-CoV-2 infection, and could be used for SARS-CoV-2 infection as diagnostic and therapeutic biomarkers.
Collapse
|
3
|
Latini A, Borgiani P, Novelli G, Ciccacci C. miRNAs in drug response variability: potential utility as biomarkers for personalized medicine. Pharmacogenomics 2020; 20:1049-1059. [PMID: 31559917 DOI: 10.2217/pgs-2019-0089] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
MicroRNAs (miRNAs) are 18-22 nucleotide RNA molecules that modulate the expression of multiple protein-encoding genes at the post-transcriptional level. Almost all physiological conditions are probably modulated by miRNAs, including pharmacological response. Indeed, acting on the regulation of numerous genes involved in the pharmacokinetics and pharmacodynamics of drugs, differences in the levels of circulating miRNAs or genetic variants in the sequences of the miRNA genes can contribute to interindividual variability in drug response, both in terms of toxicity and efficacy. For their stability in body fluids and the easy availability and accurate quantification, miRNAs could be ideal biomarkers of individual response to drugs. This review aims to give an overview on the available studies that have investigated the relationship between miRNAs and response to drugs in different classes of diseases and considered their possible clinical application as therapy response predictive biomarkers. A comprehensive search was conducted from the international web database PubMed. We included papers that investigated the relationship between miRNAs and response to drugs, published before January 2019.
Collapse
Affiliation(s)
- Andrea Latini
- Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133, Rome, taly
| | - Paola Borgiani
- Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133, Rome, taly
| | - Giuseppe Novelli
- Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133, Rome, taly.,IRCCS Neuromed, 86077, Pozzilli, IS, Italy
| | - Cinzia Ciccacci
- Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133, Rome, taly.,UniCamillus, Saint Camillus International University of Health Sciences, 00131, Rome, Italy
| |
Collapse
|
4
|
Shahid M, Idrees M, Butt AM, Raza SM, Amin I, Rasul A, Afzal S. Blood-based gene expression profile of oxidative stress and antioxidant genes for identifying surrogate markers of liver tissue injury in chronic hepatitis C patients. Arch Virol 2020; 165:809-822. [PMID: 32103340 DOI: 10.1007/s00705-020-04564-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Accepted: 01/27/2020] [Indexed: 12/16/2022]
Abstract
Oxidative stress is the process by which reactive molecules and free radicals are formed in cells. In this study, we report the blood-based gene expression profile of oxidative stress and antioxidant genes for identifying surrogate markers of liver tissue in chronic hepatitis C (CHC) patients by using real-time PCR. A total of 144 untreated patients diagnosed with CHC having genotype 3a and 20 healthy controls were selected for the present study. Liver biopsy staging and grading of CHC patients were performed using the METAVIR score. Total RNA was extracted from liver tissue and blood samples, followed by cDNA synthesis and real-time PCR. The relative expression of genes was calculated using the ΔΔCt method. The expression profile of 84 genes associated with oxidative stress and antioxidants was determined in liver tissue and blood samples. In liver tissue, 46 differentially expressed genes (upregulated, 27; downregulated, 19) were identified in CHC patients compared to normal samples. In blood, 61 genes (upregulated, 51; downregulated; 10) were significantly expressed in CHC patients. A comparison of gene expression in liver and whole blood showed that 20 genes were expressed in a similar manner in the liver and blood. The expression levels of commonly expressed liver and blood-based genes were also correlated with clinical factors in CHC patients. A receiver operating curve (ROC) analysis of oxidative stress genes (ALB, CAT, DHCR24, GPX7, PRDX5, and MBL2) showed that infections in patients with CHC can be distinguished from healthy controls. In conclusion, blood-based gene expression can reflect the behavior of oxidative stress genes in liver tissue, and this blood-based gene expression study in CHC patients explores new blood-based non-invasive biomarkers that represent liver damage.
Collapse
Affiliation(s)
- Muhammad Shahid
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan.
| | - Muhammad Idrees
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan.,Hazara University, Mansehra, Pakistan
| | - Azeem Mehmood Butt
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan.,Department of Bioscience, COMSATS University Islamabad, Islamabad, Pakistan
| | - Syed Mohsin Raza
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan.,Institute of Biomedical and Allied Health Sciences, University of Health Science, Lahore, Pakistan
| | - Iram Amin
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan
| | - Afza Rasul
- Department of Statistic, Lahore College for Women University, Lahore, Pakistan
| | - Samia Afzal
- Divison of Molecular Virology, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan
| |
Collapse
|
5
|
Jadideslam G, Ansarin K, Sakhinia E, Babaloo Z, Abhari A, Ghahremanzadeh K, Khalili M, Radmehr R, Kabbazi A. Diagnostic biomarker and therapeutic target applications of miR-326 in cancers: A systematic review. J Cell Physiol 2019; 234:21560-21574. [PMID: 31069801 DOI: 10.1002/jcp.28782] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 04/14/2019] [Accepted: 04/17/2019] [Indexed: 12/11/2022]
Abstract
MicroRNAs (miRNAs) are endogenous mediators of RNA interference and have key roles in the modulation of gene expression under healthy, inflamed, stimulated, carcinogenic, or other cells, and tissues of a pathological state. Many studies have proved the association between miRNAs and cancer. The role of miR-326 as a tumor suppressor miRNA in much human cancer confirmed. We will explain the history and the role of miRNAs changes, especially miR-326 in cancers and other pathological conditions. Attuned with these facts, this review highlights recent preclinical and clinical research performed on miRNAs as novel promising diagnostic biomarkers of patients at early stages, prediction of prognosis, and monitoring of the patients in response to treatment. All related publications retrieved from the PubMed database, with keywords such as epigenetic, miRNA, microRNA, miR-326, cancer, diagnostic biomarker, and therapeutic target similar terms from 1899 to 2018 with limitations in the English language. Recently, researchers have focused on the impacts of miRNAs and their association in inflammatory, autoinflammatory, and cancerous conditions. Recent studies have suggested a major pathogenic role in cancers and autoinflammatory diseases. Investigations have explained the role of miRNAs in cancers, autoimmunity, and autoinflammatory diseases, and so on. The miRNA-326 expression has an important role in cancer conditions and other diseases.
Collapse
Affiliation(s)
- Golamreza Jadideslam
- Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.,Internal Medicine Department, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Molecular Medicine, Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Faculty of Medicine, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Internal Medicine, Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Khalil Ansarin
- Department of Internal Medicine, Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ebrahim Sakhinia
- Internal Medicine Department, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Department of Medical Genetics, Faculty of Medicine and Tabriz Genetic Analysis Centre (TGAC), Tabriz University of Medical Sciences, Tabriz, Iran
| | - Zohreh Babaloo
- Department of Immunology Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Alireza Abhari
- Division of Clinical Biochemistry, Department of Biochemistry and Clinical Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Kazem Ghahremanzadeh
- Labratory Medicine, Central laboratory of East Azerbaijan, Tabriz University of Medical Science, Tabriz, Iran
| | - Mohamadreza Khalili
- Labratory Medicine, Central laboratory of East Azerbaijan, Tabriz University of Medical Science, Tabriz, Iran
| | - Rahman Radmehr
- Labratory Medicine, Central laboratory of East Azerbaijan, Tabriz University of Medical Science, Tabriz, Iran
| | - Alireza Kabbazi
- Internal Medicine Department, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
6
|
Jiao X, Fan Z, Chen H, He P, Li Y, Zhang Q, Ke C. Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. J Med Virol 2017; 89:1597-1605. [PMID: 28401565 DOI: 10.1002/jmv.24829] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 03/08/2017] [Indexed: 02/05/2023]
Abstract
MicroRNA (miRNA), which has been shown to correlate with liver functions, has been proposed as a new biomarker reflecting liver injury. The aim of the study was to investigate miRNA-122 (miR-122) and mir-RNA-199a (miR-199a) as a biomarker for predicting therapeutic efficacy in hepatitis C (HepC) patients. A total of 47 HepC 1b patients and 16 healthy subjects were enrolled in the study. Serum and exosomal mir-RNAs and other conventional biomarkers reflecting liver function were evaluated. The miR-122 levels in serum (miR-122ser ) and exosomes (miR-122exo ) were significantly lower in the Hepatitis C virus (HCV) genotype 1b patients than in the normal controls, but these levels were higher compared to the non-genotype 1b group. The mean miR-122ser level in the sustained virological response (SVR) group was significantly higher than that in the non-response (NR) group (P < 0.01), and the miR-122exo level in the SVR group was also higher than that in the NR group (P > 0.05), although this difference was not significant. miR-199a levels showed similar trends with the miR-122 levels in serum and exosomes. HCV RNAser was negatively correlated with the miR-122ser (r = -0.473, P = 0.004) and miR-122exo (r = -0.424, P = 0.009) levels. miR-122ser levels were positively associated with miR-199aser levels (r = 0.453, P = 0.002). Univariate and multivariate regression analyses reveal that the miR-122ser levels and ALT/AST ratio demonstrated a predictive value in evaluating patient outcomes. Serum miR-122 and miR-199a are potential biomarkers that reflect therapeutic efficacy.
Collapse
Affiliation(s)
- Xiaoyang Jiao
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
| | - Zhicheng Fan
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
- Department of Clinical Laboratory, Henan Province Hospital of Traditional Chinese Medicine, Second Affiliated Hospital of Henan University of TCM, Henan, P.R. China
| | - Huanzhu Chen
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
| | - Ping He
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
| | - Yazhen Li
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
| | - Qiaoxin Zhang
- The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, P.R. China
| | - Changwen Ke
- Cell Biology and Genetics Department, Shantou University Medical College, Shantou, Guangdong, P.R. China
- Center for Disease Control and Prevention of Guangdong Province, Guangzhou
| |
Collapse
|
7
|
Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep 2016; 6:34935. [PMID: 27731343 PMCID: PMC5059729 DOI: 10.1038/srep34935] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Accepted: 09/20/2016] [Indexed: 12/15/2022] Open
Abstract
Staging fibrosis is crucial for the prognosis and to determine the rapid need of treatment in patients with chronic hepatitis B (CHB) and C (CHC). The expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4). In CHB patients, the model (serum miR-122, serum miR-222, platelet count and alkaline phosphatase) was more accurate than APRI and FIB-4 to discriminate in between mild and moderate fibrosis (F1-F2) and F3-F4 (AUC of CHB model: 0.85 vs APRI: 0.70 and FIB-4: 0.81). In CHC patients, the model (hepatic miR-122, hepatic miR-224, platelet count, albumin and alanine aminotransferase) was more accurate than both APRI and FIB-4 to discriminate in between patients with F3-F4 and F1-F2 (AUC of the CHC model = 0.93 vs APRI: 0.86 and FIB-4: 0.79). Most of the miRNAs tested were differentially expressed in patients with CHB and CHC. In particular, serum miR-122 was 28-fold higher in patients with CHB than in those with CHC. Both CHB and CHC models may help for the diagnosis of advanced fibrosis and cirrhosis (F3-F4).
Collapse
Affiliation(s)
- Kevin Appourchaux
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Safi Dokmak
- Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France; Université Paris VII Denis Diderot, Paris, France
| | - Matthieu Resche-Rigon
- Service de Biostatistique et Information Médicale, Hôpital Saint-Louis, AP-HP, ECSTRA Team, Inserm UMR1153, Paris, France
| | - Xavier Treton
- Service de gastroentérologie, MICI et Assistance Nutritive, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, France
| | - Martine Lapalus
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Charles-Henry Gattolliat
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Emmanuelle Porchet
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Michelle Martinot-Peignoux
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Nathalie Boyer
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Michel Vidaud
- UMR745 INSERM, Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Pierre Bedossa
- Service d’anatomopathologie, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, France
| | - Patrick Marcellin
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Ivan Bièche
- UMR745 INSERM, Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Emilie Estrabaud
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| | - Tarik Asselah
- INSERM, UMR1149, Team «Physiopathologie et traitements des hépatites virales», Centre de Recherche sur l’Inflammation, and Université Denis Diderot Paris 7, site Bichat, BP 416, F-75018, Paris, France
- Service d’hépatologie, PMAD Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy la Garenne, 92110 Clichy Cedex, France
- Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, Paris, France
| |
Collapse
|
8
|
Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS One 2016; 11:e0153895. [PMID: 27100663 PMCID: PMC4839712 DOI: 10.1371/journal.pone.0153895] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2015] [Accepted: 04/05/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Egypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatment response. Polymorphisms in genes encoding inhibitors of T-cell response, which have role in disease progression as Programmed Cell Death 1 (PD-1), and Cytotoxic T-Lymphocytes Antigen-4 (CTLA-4), could be candidate markers predicting treatment response. METHODS This cohort study consisted of 200 chronic HCV genotype 4 infected patients treated with PegIFN α-2a and RBV in 2 hepatology centers. Genotyping of the polymorphisms in the IL28B gene region (rs12979860), PD1.3 (rs11568821) and CTLA-4 (rs231775) was performed on DNA collected from each patient using TaqMan® genotyping assay. Groups were classified according to response into sustained virological responders (SVR), or non-responders (NR). A multivariate logistic regression analysis was used to identify potential markers, host pretreatment clinical and viral predictive factors including viral load, insulin resistance, and alpha fetoprotein (AFP) related to treatment response. RESULTS Our results showed that in a multivariate analyses IL28B C/C genotype was the most significant predictor for SVR (OR = 10.86; p<0.0001) followed by AFP (OR = 0.915; p = 0.001) then CTLA-4/G genotypes (OR = 1.948; p = 0.022). However, PD-1.3/A genotypes and platelets count were significantly related to response in univariate analysis only (OR = 1.973; p = 0.023; OR = 1.007; p = 0.009 respectively). CONCLUSION IL28B SNP, AFP level, and CTLA-4 SNP could be used in conjunction to predict treatment response in HCV genotype 4 infected Egyptian patients.
Collapse
Affiliation(s)
- Hanan H. Rizk
- Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
| | - Nadia M. Hamdy
- Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
| | - Nadia L. Al-Ansari
- Endemic Medicine Department & Hepatology Unit, Faculty of Medicine, Ain-Shams University, Cairo, Egypt
| | - Hala O. El-Mesallamy
- Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt
| |
Collapse
|